# the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases

> **NCT07339540** · EARLY_PHASE1 · RECRUITING · sponsor: **Tongji Hospital** · enrollment: 45 (estimated)

## Conditions studied

- Recurrent or Refractory Systemic Lupus Erythematosus
- Recurrent or Refractory IgG4 Related Diseases
- Recurrent or Refractory Systemic Sclerosis
- Recurrent or Refractory Idiopathic Inflammatory Myopathy
- Recurrent or Refractory ANCA Associated Vasculitis

## Interventions

- **DRUG:** V001-BCMA

## Key facts

- **NCT ID:** NCT07339540
- **Lead sponsor:** Tongji Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-04
- **Primary completion:** 2028-10-30
- **Final completion:** 2028-10-30
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07339540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07339540, "the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT07339540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*